share_log

BioVie | 8-K: Current report

BioVie | 8-K:重大事件

美股sec公告 ·  03/04 07:55
Moomoo AI 已提取核心信息
On March 4, 2024, BioVie Inc., a Nevada-based clinical-stage company, announced the entry into a material definitive agreement with ThinkEquity LLC, acting as the placement agent, for a public offering of up to 21 million shares of its Class A common stock and/or pre-funded warrants, along with common stock purchase warrants to purchase up to an additional 10.5 million shares. The offering price for the shares is set at $1.00 per share, while the pre-funded warrants are priced at $0.9999, with each warrant exercisable for one share of common stock at $0.0001 per share. The common warrants are exercisable at $1.50 per share. BioVie also issued a warrant to ThinkEquity, exercisable for 1.05 million shares at $1.25 per share. The company expects to raise approximately...Show More
On March 4, 2024, BioVie Inc., a Nevada-based clinical-stage company, announced the entry into a material definitive agreement with ThinkEquity LLC, acting as the placement agent, for a public offering of up to 21 million shares of its Class A common stock and/or pre-funded warrants, along with common stock purchase warrants to purchase up to an additional 10.5 million shares. The offering price for the shares is set at $1.00 per share, while the pre-funded warrants are priced at $0.9999, with each warrant exercisable for one share of common stock at $0.0001 per share. The common warrants are exercisable at $1.50 per share. BioVie also issued a warrant to ThinkEquity, exercisable for 1.05 million shares at $1.25 per share. The company expects to raise approximately $21 million in gross proceeds before fees and expenses, with the offering anticipated to close on March 6, 2024. The offering is made under BioVie's effective registration statement on Form S-3 and related prospectus filed with the SEC. The company plans to use the net proceeds for working capital and general corporate purposes. Prior to the offering, BioVie issued press releases on March 1 and March 4, 2024, announcing the offering and its pricing, respectively.
2024年3月4日,总部位于内华达州的临床阶段公司BioVie Inc. 宣布与作为配售代理的ThinkeQuity LLC签订实质性最终协议,公开发行最多2100万股A类普通股和/或预先筹资认股权证,以及购买最多1,050万股股票的普通股购买权证。股票的发行价格定为每股1.00美元,而预先注资的认股权证定价为0.9999美元,每份认股权证可行使一股普通股,每股0.0001美元。普通认股权证的行使价格为每股1.50美元。BioVie还向ThinkEquity发行了认股权证,可按每股1.25美元的价格行使105万股股票。该公司预计将在费用和支出前筹集约2100万美元的总收益,此次发行预计将于20...展开全部
2024年3月4日,总部位于内华达州的临床阶段公司BioVie Inc. 宣布与作为配售代理的ThinkeQuity LLC签订实质性最终协议,公开发行最多2100万股A类普通股和/或预先筹资认股权证,以及购买最多1,050万股股票的普通股购买权证。股票的发行价格定为每股1.00美元,而预先注资的认股权证定价为0.9999美元,每份认股权证可行使一股普通股,每股0.0001美元。普通认股权证的行使价格为每股1.50美元。BioVie还向ThinkEquity发行了认股权证,可按每股1.25美元的价格行使105万股股票。该公司预计将在费用和支出前筹集约2100万美元的总收益,此次发行预计将于2024年3月6日结束。此次发行是根据BioVie在S-3表格上的有效注册声明和向美国证券交易委员会提交的相关招股说明书进行的。该公司计划将净收益用于营运资金和一般公司用途。在发行之前,BioVie于2024年3月1日和3月4日发布了新闻稿,分别宣布了此次发行及其定价。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息